<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03335072</url>
  </required_header>
  <id_info>
    <org_study_id>17-22201</org_study_id>
    <secondary_id>1UG1EY028088</secondary_id>
    <nct_id>NCT03335072</nct_id>
  </id_info>
  <brief_title>Kebele Elimination of Trachoma for Ocular Health</brief_title>
  <acronym>KETFO</acronym>
  <official_title>Kebele Elimination of Trachoma for Ocular Health</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Eye Institute (NEI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Carter Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose a cluster-randomized clinical trial to determine whether an
      intensive, targeted azithromycin distribution strategy is effective for elimination of
      trachoma at the kebele level compared to the World Health Organization (WHO) recommendation
      of annual azithromycin distribution.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators propose to randomize at the kebele level, which consist of approximately 15
      villages, 4,000 residents, and are served by a single primary school. Eighty kebeles will be
      randomized to one of four arms: 1) annual mass azithromycin distribution per WHO guidelines
      (Annual); 2) annual mass azithromycin distribution plus quarterly targeted treatment of all
      children aged 0-9 years (Core Group—Age); 3) annual mass azithromycin distribution plus
      quarterly targeted treatment of all children aged 0-9 years with a positive chlamydial PCR
      test (Core Group—PCR); or 4) annual mass azithromycin distribution plus quarterly targeted
      treatment of all children aged 0-9 years positive for conjunctival inflammation as assessed
      from annual photography (Core Group—TI). The primary outcome for the trial will be the ocular
      chlamydia prevalence at 12, 24, and 36 months. Secondary outcomes will include bacterial load
      of ocular chlamydia via quantitative PCR, the prevalence of clinically active trachoma
      assessed at 12, 24, and 36 months, and serology via dried blood spot at baseline and 36
      months.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2018</start_date>
  <completion_date type="Anticipated">April 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular chlamydia measured in a population based age-stratified sample of the entire community</measure>
    <time_frame>36 months</time_frame>
    <description>Assessed by PCR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Infectious load of chlamydia among 0-9 year-old children infected with ocular chlamydia</measure>
    <time_frame>36 months</time_frame>
    <description>Assessed by PCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conjunctival inflammation</measure>
    <time_frame>36 months</time_frame>
    <description>Assessed from conjunctival photography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically active trachoma</measure>
    <time_frame>36 months</time_frame>
    <description>Measured by exam</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serology</measure>
    <time_frame>36 months</time_frame>
    <description>Assessed via Dried Blood Spot</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">320000</enrollment>
  <condition>Trachoma</condition>
  <arm_group>
    <arm_group_label>WHO-recommended</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Annual mass azithromycin distribution of all residents</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Age-based core group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Annual mass treatment of everyone plus quarterly treatment of children</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PCR infection-based core group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Annual mass treatment plus quarterly treatment of a PCR-based cohort that would be a subset of the age-based core group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TI-based core group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Annual mass treatment plus quarterly treatment of a conjunctival photography-based cohort that would be a subset of the age-based core group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>Mass Drug Administration</description>
    <arm_group_label>WHO-recommended</arm_group_label>
    <arm_group_label>Age-based core group</arm_group_label>
    <arm_group_label>PCR infection-based core group</arm_group_label>
    <arm_group_label>TI-based core group</arm_group_label>
    <other_name>Zithromax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All individuals in all communities will be eligible for annual mass azithromycin
             distribution per WHO guidelines.

        Exclusion Criteria:

          -  Those who do not consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tom M Lietman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Catherine A Cook, MPH</last_name>
    <role>Study Director</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tom M Lietman, MD</last_name>
    <phone>415-502-2662</phone>
    <email>Tom.Lietman@ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Catherine A Cook, MPH</last_name>
    <phone>415-476-4981</phone>
    <email>Catherine.Cook@ucsf.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCSF Proctor Foundation</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Carter Center</name>
      <address>
        <city>Addis Ababa</city>
        <country>Ethiopia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zerihun Tadesse, MD</last_name>
      <phone>+251-116-631863</phone>
      <email>Zerihun.Tadesse@ucsf.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>Ethiopia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2017</study_first_submitted>
  <study_first_submitted_qc>November 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2017</study_first_posted>
  <last_update_submitted>April 11, 2018</last_update_submitted>
  <last_update_submitted_qc>April 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Azithromycin</keyword>
  <keyword>Mass Drug Administration</keyword>
  <keyword>Antibiotic Resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trachoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

